XLIFE-SCIENCES-AG
Xlife Sciences AG has successfully realized its 60% stake of the project company Araxa Biosciences GmbH in Veraxa Biotech AG (formerly Velaxa AG). This transaction has a total value of more than 20 million euros and Xlife Sciences AG will now become a part of the Board of Directors of Veraxa as a minority shareholder. Veraxa Biotech AG is positioned as a leading provider in the identification and development of functional antibodies and drug conjugates.
Xlife Sciences AG will exceed its earnings expectations for 2020 with this first completed transaction since founding of the company. Araxa Biosciences GmbH was a spin-off from the European Molecular Biology Laboratory EMBL in Heidelberg and was founded by Xlife Sciences AG in summer 2019. Over the past one and a half years, Xlife has invested nearly one million euros in the company. In collaboration with various industry experts, the technological development of Araxa has been successfully advanced.
About Veraxa Biotech AG
Veraxa Biotech AG identifies and develops functional antibodies and antibody drug conjugates (ADC's) for the bio- and pharmaceutical industry in exchange for license agreements. The aim is to accelerate the safe development of medical drugs, as well as to enhance the probabilities of drug developments in various clinical phases. Using this technology, Veraxa Biotech AG can screen millions of b-cells in one single step in less than 48 hours for functional antibodies and additionally also modify them with drug conjugates.
About Xlife Sciences AG
Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch
View source version on businesswire.com: https://www.businesswire.com/news/home/20201223005137/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AWS Launches AWS European Sovereign Cloud and Announces Expansion Across Europe15.1.2026 08:00:00 CET | Press release
AWS announces the general availability of the AWS European Sovereign Cloud and plans to expand across Europe with new AWS Local Zones in Belgium, the Netherlands, and PortugalAmazon plans to invest more than €7.8 billion in the AWS European Sovereign Cloud in Germany and support an average of 2,800 full-time equivalent jobs annually Today, Amazon Web Services (AWS) announced the general availability of the AWS European Sovereign Cloud, a new, independent cloud for Europe entirely located within the EU, and physically and logically separate from other AWS Regions. The AWS European Sovereign Cloud’s unique approach provides the only fully featured, independently operated sovereign cloud backed by strong technical controls, sovereign assurances, and legal protections designed to meet the needs of European governments and enterprises for sensitive data. AWS also announced plans to extend the AWS European Sovereign Cloud footprint from Germany across the EU to support stringent isolation, i
Cargill Advances Maritime Decarbonisation with Delivery of First Green Methanol Dual-Fuel Vessel15.1.2026 08:00:00 CET | Press release
Brave Pioneer is the first in a new fleet of chartered vessels designed to scale Cargill’s investment to low-carbon innovation across dry-bulk shipping Cargill today announced the maiden voyage of Brave Pioneer, the first of five green methanol dual-fuel dry bulk vessels chartered by the company. The deployment of the Brave Pioneer marks another important milestone in Cargill’s broader decarbonization efforts – one focused on innovation, testing and learning as the company works with customers and partners to refine future-ready solutions for Cargill and the industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114083757/en/ Built by Tsuneishi Shipbuilding Co., Ltd. and owned by Mitsui & Co. Ltd., Brave Pioneer is equipped to operate on both conventional marine fuels and green methanol, a lower-carbon alternative. Built by Tsuneishi Shipbuilding Co., Ltd. and owned by Mitsui & Co. Ltd., Brave Pioneer is equipped to ope
Axelspace Signs MoU with Ethiopian Company to Address Social Challenges through the Utilization of Satellite Data15.1.2026 07:30:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading developer and operator of microsatellites dedicated to realizing its vision of “Space within Your Reach,” has made a Memorandum of Understanding (MoU) with Jethi Software Development PLC (“Jethi”), an Ethiopian technology company, to cooperate on addressing social and development challenges through the utilization of satellite-based Earth observation (EO) data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114413353/en/ Naol Debele, Chief Executive Officer of Jethi (left), and Yuya Nakamura, President and CEO of Axelspace, at the signing ceremony on January 13 in Ethiopia The MoU was signed by Naol Debele, Chief Executive Officer of Jethi, and Yuya Nakamura, President and CEO of Axelspace. The signing ceremony, held in Ethiopia on January 13 (local time), was attended by representatives of the Space Science and Geospatial Institute (SSGI) of Ethiopia, members of the Jethi Bo
Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference15.1.2026 01:40:00 CET | Press release
Samsung Bioepis plans to secure 20 biosimilars in its products and pipeline by 2030The new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki, vedolizumab, and ocrelizumab, in addition to pembrolizumab currently in Phase 1 and 3 clinical studiesHaving secured investigational new drug application (IND) clearance from the U.S. Food and Drug Administration (FDA), SBE303, Samsung Bioepis’ novel antibody-drug conjugate (ADC) engineered to target Nectin-4, will enter into the Phase 1 first-in-human clinical trial this yearSamsung Bioepis plans to add one novel therapeutic candidate in clinical study every year Samsung Epis Holdings (KRX: 0126Z0) today shared corporate progress and updates at the 44th J.P. Morgan Healthcare Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114206458/en/ Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings "2026 is a mon
Most Delivered Light-Entry Jet Cessna Citation M2 Gen2 With Garmin Autothrottles Enters Into Service, Bringing Greater Control and Precision to Pilots14.1.2026 20:30:00 CET | Press release
The Cessna Citation M2 Gen2 with Garmin Autothrottles recently entered into service. Certified by the Federal Aviation Administration in October 2025, the integration of Garmin’s Autothrottle system in the Citation M2 Gen2 further supports the most delivered light-entry jet’s capabilities by bringing greater control and precision to pilots. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114646844/en/ Most delivered light-entry jet Cessna Citation M2 Gen2 with Garmin Autothrottles enters into service, bringing greater control and precision to pilots (Photo Credit: Textron Aviation). The Cessna Citation M2 Gen2 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “We continue to invest in our products to provide customers with the best aviation experience in the world," said Lannie O’Bannion, senior vice president, Sales & Marketing. “The M2 Gen2 leads its segment as the most delivered
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom